These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

305 related articles for article (PubMed ID: 24579736)

  • 1. Optimization of immunotherapy in elderly cancer patients.
    Tomihara K; Curiel TJ; Zhang B
    Crit Rev Oncog; 2013; 18(6):573-83. PubMed ID: 24579736
    [TBL] [Abstract][Full Text] [Related]  

  • 2. siRNA and cancer immunotherapy.
    Ghafouri-Fard S; Ghafouri-Fard S
    Immunotherapy; 2012 Sep; 4(9):907-17. PubMed ID: 23046235
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Immunotherapy of cancer.
    Borghaei H; Smith MR; Campbell KS
    Eur J Pharmacol; 2009 Dec; 625(1-3):41-54. PubMed ID: 19837059
    [TBL] [Abstract][Full Text] [Related]  

  • 4. In vivo cancer vaccination: Which dendritic cells to target and how?
    Chiang CL; Kandalaft LE
    Cancer Treat Rev; 2018 Dec; 71():88-101. PubMed ID: 30390423
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cancer, aging and immunotherapy: lessons learned from animal models.
    Lustgarten J
    Cancer Immunol Immunother; 2009 Dec; 58(12):1979-89. PubMed ID: 19238382
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Considerations for successful cancer immunotherapy in aged hosts.
    Hurez V; Padrón ÁS; Svatek RS; Curiel TJ
    Clin Exp Immunol; 2017 Jan; 187(1):53-63. PubMed ID: 27690272
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Mechanisms of murine dendritic cell antitumor dysfunction in aging.
    Grolleau-Julius A; Abernathy L; Harning E; Yung RL
    Cancer Immunol Immunother; 2009 Dec; 58(12):1935-9. PubMed ID: 19082999
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Considerations for successful cancer immunotherapy in aged hosts.
    Hurez V; Padrón Á; Svatek RS; Curiel TJ
    Exp Gerontol; 2018 Jul; 107():27-36. PubMed ID: 28987644
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Dendritic cell engineering for tumor immunotherapy: from biology to clinical translation.
    Bhargava A; Mishra D; Banerjee S; Mishra PK
    Immunotherapy; 2012 Jul; 4(7):703-18. PubMed ID: 22853757
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Dendritic cell immunotherapy for the treatment of neoplastic disease.
    Decker WK; Xing D; Shpall EJ
    Biol Blood Marrow Transplant; 2006 Feb; 12(2):113-25. PubMed ID: 16443510
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Chemical Strategies to Enhance the Therapeutic Efficacy of Toll-like Receptor Agonist Based Cancer Immunotherapy.
    Lee SN; Jin SM; Shin HS; Lim YT
    Acc Chem Res; 2020 Oct; 53(10):2081-2093. PubMed ID: 32966047
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Dendritic cell-based vaccines and therapies for cancer.
    Tatsumi T; Storkus WJ
    Expert Opin Biol Ther; 2002 Dec; 2(8):919-28. PubMed ID: 12517270
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Yeast virus-derived stimulator of the innate immune system augments the efficacy of virus vector-based immunotherapy.
    Claudepierre MC; Hortelano J; Schaedler E; Kleinpeter P; Geist M; Remy-Ziller C; Brandely R; Tosch C; Laruelle L; Jawhari A; Menguy T; Marchand JB; Romby P; Schultz P; Hartmann G; Rooke R; Bonnefoy JY; Preville X; Rittner K
    J Virol; 2014 May; 88(10):5242-55. PubMed ID: 24574403
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Dendritic cells in tumor immunology and immunotherapy.
    Turtle CJ; Hart DN
    Curr Drug Targets; 2004 Jan; 5(1):17-39. PubMed ID: 14738216
    [TBL] [Abstract][Full Text] [Related]  

  • 15. MUC1 immunotherapy.
    Beatson RE; Taylor-Papadimitriou J; Burchell JM
    Immunotherapy; 2010 May; 2(3):305-27. PubMed ID: 20635898
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Dendritic cell-based cancer immunotherapies.
    Fujii S; Takayama T; Asakura M; Aki K; Fujimoto K; Shimizu K
    Arch Immunol Ther Exp (Warsz); 2009; 57(3):189-98. PubMed ID: 19479202
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Promising preclinical platform for evaluation of immuno-oncology drugs using Hu-PBL-NSG lung cancer models.
    Pyo KH; Kim JH; Lee JM; Kim SE; Cho JS; Lim SM; Cho BC
    Lung Cancer; 2019 Jan; 127():112-121. PubMed ID: 30642538
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Dendritic cell preparation for immunotherapeutic interventions.
    Simon T; Fonteneau JF; Grégoire M
    Immunotherapy; 2009 Mar; 1(2):289-302. PubMed ID: 20635946
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Immunotherapy of tumors with recombinant adenovirus encoding macrophage inflammatory protein 3beta induces tumor-specific immune response in immunocompetent tumor-bearing mice.
    Hou JM; Zhao X; Tian L; Li G; Zhang R; Yao B; Deng HX; Yang JL; Wei YQ
    Acta Pharmacol Sin; 2009 Mar; 30(3):355-63. PubMed ID: 19262559
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Immune based therapies in cancer.
    Krüger C; Greten TF; Korangy F
    Histol Histopathol; 2007 Jun; 22(6):687-96. PubMed ID: 17357098
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.